Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis.

Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis. - Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013033

Enrollment

Registered

2014-02-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Study start - 14 weeks:5mg/kg of Infliximab for 0.2.6.14 week, respectively ( initial administration day with 0 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with steroid dependence, resistant ulcerative colitis moderate disease.(Mayo Score 6-10) 2. Being 20 years old or older 3, A document agreement by the free will of the patients person himself being obtained in the thing which understands it enough after having received enough explanation on participating of this study

Exclusion criteria

Exclusion criteria: 1. The patients with serious infection (sepsis) 2. The patients with active tuberculosis 3. The patients with a history of sensitivity to protein(mouse type, a chimeric type, humanized antibody) derived from a mouse or ingredient of the Infliximab 4. The patients with a history of demyelinating diseases (Multiple sclerosis) 5. The patients with congestive heart failure 6. The patients that doctor attending judged an arrangement to this study to be inappropriate

Design outcomes

Primary

Measure	Time frame
Mayo score percent improvement 6-14 weeks after the administration.	—

Countries

Japan

Contacts

Public ContactTaro Osada

Department of Internal Medicine,Juntendo University Department of Gastroenterology

otaro@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026